



MARKET RELEASE

4 April 2017

Prescient Therapeutics Limited

TRADING HALT

The securities of Prescient Therapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 6 April 2017 or when the announcement is released to the market.

Security Code: PTX

Kobe Li

SENIOR ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



4 April 2017

Mr Kobe Li
ASX Limited
Level 4, North Tower
525 Collins Street
MELBOURNE VIC 3000

(By email: Zheng.Li@asx.com.au)

REQUEST FOR TRADING HALT

In accordance with Listing Rule 17.1 the Company requests an immediate trading halt on its securities (PTX and PTXO) pending the release of an announcement to the market in relation to results from the Company's Phase 1b Breast Cancer trial.

The trading halt is requested until the earlier of the release of the announcement or prior to commencement of trading on Thursday 6 April 2017.

The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely,
Prescient Therapeutics Limited

A handwritten signature in black ink, appearing to read "Melanie Leydin", is written over a light blue horizontal line.

Melanie Leydin
Company Secretary